(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
5 High Limit Outer Hard Drives For Information Stockpiling - 23D Printers for Specialists
- 3Figure out How to Utilize Your Web based Advertising Degree to Break into the Tech Business
- 4Monetary Security: Building Serious areas of strength for an Establishment
- 56 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- Remain Fit and Sound with These Exercise Fundamentals
- Best Vegetarian Dinner: What's Your Plant-Based Pick?
- Becoming the best at Discussion: Individual Procedures
- Find the Lively Food Markets of South America
- The most effective method to Consummate the Specialty of Handshaking in Business and Group environments
- The Most Rousing Ladies Business visionaries of Today
- The Fate of Rest: Patterns in Shrewd Beds
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- 5 Great and High Evaluated Scene Configuration Administrations For 2024
